Navigation Links
Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs

TORONTO, March 24, 2011 /PRNewswire/ -- The Ontario Institute for Cancer Research (OICR) announced today it has made an investment to accelerate commercialization of a potentially revolutionary high-throughput screening technology directed at the discovery of anticancer drugs. The technology, Smart Well Plate™, developed at the University of Toronto, is a palm-sized device that utilizes digital microfluidics (DMF), a technique that allows manipulation of cells and tiny droplets of liquid on an open platform with no moving parts.

"The Smart Well-Plate technology may allow for less expensive screening of chemical libraries and elimination of false leads earlier in the drug discovery process, ensuring a higher success rate for clinical trials focused on cancer," said Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of OICR. "OICR's investment is engineered to move this promising technology closer to commercialization."

High-throughput screening, or HTS, is the universal first step in drug development, allowing chemists and scientists to test biological samples with chemical entities as a starting point for drug design and for understanding a particular biochemical process. It combines robotics with data computing, liquid handling devices, and sensitive detectors that allow researchers to quickly conduct millions of biochemical, genetic or pharmacological tests. The HTS process allows for rapid identification of active compounds, antibodies or genes that modulate a particular biochemical pathway.

In recent years, the introduction of microfluidics has improved the HTS process by miniaturizing cell-based assays. However, the process is limited by the complexity of controlling the reagents simultaneously in interconnected channels. In addition, microfluidics heavily relies upon robotics.

DMF takes the screening concept a step further, by reducing robotics and simplifying reagent handling. It allows droplets containing mammalian cells to be addressed with compounds from chemical libraries in a highly efficient and low-cost manner, allowing automated, fast, and reliable analysis of chemical entities. Most importantly, a much smaller amount of cells and reagents are required to do the same testing.

The principal investigators for the Smart Well Plate™ are Dr. Aaron Wheeler, Associate Professor of Chemistry at the University of Toronto, and internationally recognized analytical chemist and renowned cancer expert Dr. Jeff Wrana, Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto.

"Ontario is proud to be home to world-class researchers like Dr. Aaron Wheeler and Dr. Jeff Wrana," said Glen Murray, Ontario's Minister of Research and Innovation. "Along with supporting the pursuit of new and better cancer treatments, the province's investments in OICR are helping promote R&D commercialization, capitalizing on opportunities to develop new technologies and create jobs."

OICR's investment is administered through the Intellectual Property Development and Commercialization Program, which provides seed funding for late stage academic projects that meet specific market-oriented criteria.  

OICR will work closely with MaRS Innovation, the lead commercialization agent for this technology and the Innovations & Partnerships Office of the University of Toronto to support effective commercialization.

About OICR

OICR, based in Ontario, Canada, is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. OICR has 500 scientific staff (located at its headquarters and in research institutes and academia across the Province of Ontario) and an $85 million annual operating budget. It has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase I clinical trials.

For more information, please visit the website at

Rhea Cohen
Director of Communications
Telephone: 416-673-6642
Mobile: 416-671-2846

SOURCE The Ontario Institute for Cancer Research
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
2. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
3. Koch Institute for Integrative Cancer Research Dedicated Today
4. Sharpest microscope tip lands Canadas Nanotech Institute in Guinness Book of World Records
5. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
6. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
7. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
8. Tufts Launches Institute for Biopharmaceutical Partnerships
9. Salk Institute Celebrates Grand Opening of the Waitt Advanced Biophotonics Center
10. Will Rogers Institute Awards Top Doctor $50,000 for Outstanding Contributions to Lung Research
11. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
Breaking Biology News(10 mins):